Skip to Content

Lumos Pharma Inc LUMO Stock Quote

| Rating as of


After hours: 2.81 0.00 | 0.00 %

| Currency in USD

  • Last Close 2.93
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 2.72  –  2.81
  • Year Range 2.63  –  9.53
  • Market Cap 22.2986 Mil
  • Volume / Avg 2,130.0 /  19,409.0
  • Price / Sales 15.78
  • Price / Book 0.54
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis LUMO

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LUMO

Company Profile LUMO

Business Description

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

4200 Marathon Boulevard, Suite 200
Austin, TX, 78756
Industry Biotechnology
Employees 32

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

Lumos Pharma Inc


Genocea Biosciences Inc


Syndax Pharmaceuticals Inc


Viking Therapeutics Inc

−$0.12 (4.10%) $0.00 (0.00%) −$0.25 (1.57%) −$1.22 (9.43%)
Market Cap
22.30 Mil11,756.701.09 Bil1.17 Bil
Biotechnology Biotechnology Biotechnology Biotechnology

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Lumos Pharma Inc Stock

No. LUMO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

LUMO’s market cap is 22.30 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

LUMO’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

LUMO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare LUMO’s historical performance against its industry peers and the overall market.